Skip to search formSkip to main contentSkip to account menu

CEP-701

Known as: CEP 701, CEP701 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lestaurtinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients.
Abstract 753 Since the seminal discovery of the JAK2V617F mutation, small molecule inhibitors of JAK2 to treat patients with… 
2009
2009
A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).
Abstract 754 Introduction: The identification of mutations in JAK2 in myeloproliferative neoplasms (MPN) has led to the… 
2008
2008
Testing magnetically confined wind shock models for β Cephei using XMM-Newton and Chandra phase-resolved X-ray observations
Aims. We have performed a set of high- and low-spectral resolution phase-resolved X-ray observations of the magnetic B star β Cep… 
2008
2008
An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis
Polycythemia vera (PV) and essential thrombocytosis (ET) are clonal hematopoietic stem cell disorders characterized by the over… 
2008
2008
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas
SummaryIntroduction: Current standard therapy for advanced pancreas cancer includes the use of gemcitabine or a gemcitabine-based… 
2007
2007
D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia
MLL rearranged and hyperdiploid acute lymphoblastic leukemia (ALL) are characterized by high-level FLT3 expression and… 
Highly Cited
2007
Highly Cited
2007
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells
Activating mutation of FLT3 by internal tandem duplications (ITDs) in the juxtamembrane region is the most common molecular… 
2007
2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint
PURPOSE: CEP-701 is a potent inhibitor of trk receptors that causes cell death in prostate cancer (PC) models. CEP-701 binds to… 
2005
2005
Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.
We undertook a study to compare two small molecule FLT3 inhibitors, CEP-701(lestaurtinib) and PKC-412. Both compounds have been… 
1999
1999
DO WE REALLY OBTAIN RELIABLE ELEMENTAL ABUNDANCES FOR SUPERGIANT STARS
We discuss the problems of standard spectroscopic analysis of intermediate mass supergiants and propose the usage of Fe ii lines… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)